China Pharma Correlations
| CPHI Stock | USD 0.32 0.01 3.03% |
The correlation of China Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as China Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if China Pharma Holdings moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Significant diversification
The correlation between China Pharma Holdings and NYA is 0.05 (i.e., Significant diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding China Pharma Holdings and NYA in the same portfolio, assuming nothing else is changed.
China |
The ability to find closely correlated positions to China Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace China Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back China Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling China Pharma Holdings to buy it.
Moving against China Stock
| 0.81 | VKTX | Viking Therapeutics Earnings Call Today | PairCorr |
| 0.79 | ELEV | Elevation Oncology Financial Report 20th of May 2024 | PairCorr |
| 0.73 | NRSNW | NeuroSense Therapeutics | PairCorr |
| 0.59 | XFOR | X4 Pharmaceuticals Financial Report 2nd of May 2024 | PairCorr |
| 0.54 | LLY | Eli Lilly Earnings Call This Week | PairCorr |
| 0.46 | BMY | Bristol Myers Squibb Earnings Call Tomorrow | PairCorr |
| 0.42 | CGC | Canopy Growth Corp Trending | PairCorr |
| 0.72 | ARQT | Arcutis BiotherapeuticsI Financial Report 14th of May 2024 | PairCorr |
Related Correlations Analysis
Please specify at least 3 valid symbols having historical data to build a meaningful correlation cloud. You can use symbol search above to locate your securities.
Be your own money manager
Our tools can tell you how much better you can do entering a position in China Pharma without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Sectors Now
SectorsList of equity sectors categorizing publicly traded companies based on their primary business activities |
| All Next | Launch Module |
China Pharma Corporate Directors
China Pharma corporate directors refer to members of a China Pharma board of directors. The board of directors generally takes responsibility for the China Pharma's affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of China Pharma's board members must vote for the resolution. The China Pharma board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.| Baowen Dong | Independent Director | Profile | |
| Yingwen Zhang | Independent Director | Profile | |
| Gene Bennett | Independent Director | Profile | |
| Heung Tsui | Director | Profile |
Already Invested in China Pharma Holdings?
The danger of trading China Pharma Holdings is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of China Pharma is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than China Pharma. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile China Pharma Holdings is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether China Pharma Holdings offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of China Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of China Pharma Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on China Pharma Holdings Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in China Pharma Holdings. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in rate. Note that the China Pharma Holdings information on this page should be used as a complementary analysis to other China Pharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Complementary Tools for China Stock analysis
When running China Pharma's price analysis, check to measure China Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy China Pharma is operating at the current time. Most of China Pharma's value examination focuses on studying past and present price action to predict the probability of China Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move China Pharma's price. Additionally, you may evaluate how the addition of China Pharma to your portfolios can decrease your overall portfolio volatility.
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios |
Is China Pharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of China Pharma. If investors know China will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about China Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.91) | Revenue Per Share 2.072 | Quarterly Revenue Growth (0.26) | Return On Assets (0.10) | Return On Equity (0.52) |
The market value of China Pharma Holdings is measured differently than its book value, which is the value of China that is recorded on the company's balance sheet. Investors also form their own opinion of China Pharma's value that differs from its market value or its book value, called intrinsic value, which is China Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because China Pharma's market value can be influenced by many factors that don't directly affect China Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between China Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if China Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, China Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.